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Indigofera truxillensis and I. suﬀruticosa, are used as a source of indigo dye and to treat several diseases. The mutagenic activity
of the methanolic extracts from aerial parts, glycerolipid, ﬂavonoid and alkaloid fractions of the extract were evaluated by means
of Salmonella/microsome assays using TA100, TA98, TA102 and TA97a strains. The methanolic extract of I. truxillensis showed
mutagenic activity in the TA98 strain without S9 while glycerolipid fraction was devoid of activity. The ﬂavonoid and alkaloid
fractions of both plants showed mutagenicity. Chemical analysis of ﬂavonoid fractions of I. truxillensis and I. suﬀruticosa resulted
in the identiﬁcation of kaempferol, quercetin and their derivatives. The alkaloid fraction of both the species contained indigo and
indirubin and indigo was found mainly responsible for the mutagenic activity.
1.Introduction
Indigofera truxillensis and I. suﬀruticosa (family Fabaceae)
are common plants of the Brazilian savannah. The genus
Indigofera isknowntobearichsourceofﬂavonoidglycosides
[1, 2] and indigo derivatives (bis indoles) [3] and nitro
compounds [4]. Indigofera truxillensis Kunth is reported
to be antiulcerogenic and antioxidant [5, 6]. Indigofera
suﬀruticosa Miller is used as a source of indigo dye and
in popular medicine as an antimicrobial, purgative, anti-
spasmodic, sedative, diuretic, to treat epilepsy, stomach
and urinary diseases, jaundice, ulcers, intermittent fevers,
hepatitis, as an antidote for snake venom and bee bites and
to stimulate the central nervous system [7]. Recently it was
found highly eﬀective in inhibiting growth of solid tumors
[8] and showed antibacterial and antifungal activities [9].
Investigation of traditionally used medicinal plants is
thus valuable as a source of potential chemotherapeutic
drugsand asameasure ofsafety forthecontinueduse. Plants
are used to treat various ailments, however, some medicinal
plants can be with serious risks to humans health [10].
The Salmonella mutagenicity test (Ames test) identify if any
sample provoke the mutation of genetically modiﬁed DNA
of selected S. typhimurium strains and is used worldwide
as an initial screening of the mutagenic potential of new
chemicalsforhazard identiﬁcationandfortheregistration or
acceptance of new chemicals by regulatory agencies [11, 12].
In spite of the many beneﬁcial actions of plants, it is
important to emphasize that some of their constituents can
be poisonous to the organism, and metabolism of ingested
plants can also generate toxic metabolites. Many carcinogens
remain inactive until they are enzymatically transformed to
an electrophilic species that is capable of covalently binding
to DNA, leading to mutation. For this reason, metabolic
activation is considered to be a critical step in mutagenesis
[13–16].2 Evidence-Based Complementary and Alternative Medicine
Short-term tests that detect genetic damage can provide
information needed to evaluate carcinogenic risks of chem-
icals to humans. The Ames test, recommended for testing
the mutagenicity of chemical compounds with potential
pharmacologicalapplication[12,17],wasusedinthepresent
study to evaluate the putative mutagenic eﬀect of the
methanolic extracts of I. truxillensis, I. suﬀruticosa, ﬂavonoid
and alkaloid fractions including indigo and indirubin.
2.Methods
2.1. Chemicals. Dimethylsulfoxide (DMSO), nicotinamide
adenine dinucleotide phosphate sodium salt (NADP), d-
glucose-6-phospate disodium salt, l-histidine monohydrate,
d-biotin, standard mutagens: sodium azide, 2-anthramine,
mitomycin C and 4-nitro-o-phenylenediamine were pur-
chased from Sigma Chemical Co. (St Louis, MO, USA). All
other reagents used for chemical analysis and to prepare
buﬀers and media were from Merck (Whitehouse Station,
NJ) and Sigma.
2.2. Plant Material. Aerial parts of plants were collected
in Rubi˜ ao Junior, Botucatu city, S˜ ao Paulo State, Brazil,
and authenticated by Prof. Dr Jorge Yoshio Tamashiro. The
voucher specimens of I. suﬀruticosa Miller (HUEC 129598)
and I. truxillensis Kunth (HUEC 131827) were deposited at
t h eH e r b a r i u mo ft h eU n i v e r s i d a d eE s t a d u a ld eC a m p i n a s
(Unicamp), Campinas, SP, Brazil.
2.3. Extraction and Isolation. Air-dried aerial parts of the
plants (1.5kg) were powdered, extracted with chloroform
(CHCl3) and methanol (MeOH) successively at room tem-
perature (3 × 72 hours, each solvent). Solvents were ﬁltered
and evaporated at 35◦C under reduced pressure, aﬀording
the CHCl3 and MeOH extracts, respectively. Indigofera
truxillensis yielded 43.0g (2.9%) of CHCl3 and 110.0g
(7.3%)ofMeOHextract,whileI.suﬀruticosafurnished18.5g
(1.2%) of CHCl3 and 41.3g (2.7%) of MeOH extract. The
MeOH extracts of both Indigofera species were fractionated
in analogous ways by gel permeation chromatography. An
aliquot of the MeOH extract of the each plant (2.8g) was
subjected to column chromatography on Sephadex LH-
20 (∼ 130 fractions of 20ml), using methanol as eluent,
ﬂowing at 0.5ml/minutes. The collected fractions were com-
bined into fractions A–C, after thin layer chromatography
(TLC) analysis on silica-gel TLC plates on glass (20 ×
20cm), run with a solvent mixture composed of butanol
:a c e t i ca c i d:w a t e r( 4:1:2 ,v:v:v ) ,v i s u a l i z e d
by UV light (254 and 365 nm) and then sprayed with
diphenylaminoborate/polyethyleneglycol (NP/PEG) reagent
or anisaldehyde/sulfuric acid solution to develop the spots
[18].
Fraction A, obtained from the MeOH extracts of each
species of Indigofera, was analyzed by direct injection ESI-
IT-MS/MS (electrospray ionization ion trap tandem mass
spectrometry), which demonstrated that this fraction con-
tained glycerolipids. Fraction B, denominated the ﬂavonoid
fraction, was puriﬁed by column chromatography on
polyvinylpyrrolidone, eluted with MeOH and MeOH:water
(80 : 20, v : v), or MPLC (medium-pressure liquid chro-
matography) on silica-gel, eluted with EtOAc : MeOH under
gradient conditions, followed by semi-preparative reversed-
phase HPLC on C-18 silica-gel, eluted with MeOH : water
(80 :20; 60: 40, v : v).The puriﬁcationofthe fractionB from
I. truxillensis and I. suﬀruticosa aﬀorded ﬂavonol derivatives
of kaempferol and quercetin, respectively.
Fraction C, denominated the alkaloid fractions, obtained
from the MeOH extracts of I. truxillensis and I. suﬀruticosa,
was chromatographed by Sephadex LH-20 column and
exhibited bis-indole alkaloids. Where necessary, fractiona-
tion of the MeOH extracts was repeated to obtain larger
quantities of fractions B (ﬂavonoid fraction) and C (alkaloid
fraction). Compounds in fractions B and C were identiﬁed
by MS (mass spectrometry), 1D and 2D NMR (nuclear mag-
neticresonance)techniquesandconﬁrmedbycomparingthe
physical and spectroscopic/spectrometric data (NMR and
MS) with those in the literature.
2.4. General Experimental Procedures. NMR spectra were
obtained on a Varian Inova-500 NMR spectrometer using
the solvent DMSO-d6 with tetramethylsilane as internal
standard. Electrospray ionization mass spectrometry was
performed in a Fisons VG Platform instrument in the neg-
ative mode (45V). The samples were dissolved in methanol
and injected directly into the mass spectrometer through
a Rheodyne injector. Acetonitrile was used as solvent and
nitrogen was usedasthedrying gas andfornebulization.The
analyses by ESI-IT-MS/MS were performed in a Finnigan
(Thermo Finnigan, San Jose, CA, USA) LCQ Deca ion
trap instrument equipped with Xcalibur software; samples
were dissolved in methanol and infused in the eletrospray
ionisation source with a syringe pump. Precoated silica-gel
plateswith aluminum-backed sheets(Merck)were employed
for TLC with detection at 254 and 365 nm followed by color
development with NP/PEG reagent or anisaldehyde/sulfuric
acid reagent. Sephadex LH-20 columns (25–100μm, 3.0
(i.d.) × 57.0 and 1.5 (i.d.) × 30cm, Pharmacia Fine Chem-
icals), polyvinylpyrrolidone (P–6755, Sigma) and silica-gel
SiF254 (0.063–0.200mm, Merck) were used for column
chromatography. The MPLC separations were carried out
with a Baeckstr¨ om apparatus equipped with an FMIQSY lab
pump, using a silica-gel column(0.04–0.063mm, 2.0 (i.d.) ×
30cm, Merck]) Fractions were puriﬁed by HPLC in a system
equipped with an R401 refractive index detector and with a
Phenomenex Luna reversed-phase C-18 column(10mm, 1.0
(i.d.) × 25cm, Phenomenex Luna])and Rheodyne injector
with a 100μl sample loop.
2.5.S.typhimurium MutagenicityAssay. Itwas performed by
preincubating test compounds for 20–30 minutes with the S.
typhimurium strains TA100, TA98, TA97a and TA102, with
orwithout metabolic activation [11]. The S9-mix was freshly
prepared before each test with an Aroclor-1254-induced rat
liver fraction purchased (lyophilized) from Moltox (Molec-
ular Toxicology Inc.). Salmonella typhimurium strains were
kindly provided by Dr B. Ames, University of California,Evidence-Based Complementary and Alternative Medicine 3
Berkeley,CA,USA.Various concentrationsof thedry MeOH
extract (1.25–7.5mg/plate), the ﬂavonoids fraction (0.12–
2.5mg/plate), alkaloids fraction (0.12–2.5mg/plate) and iso-
latedcompounds(indigoandindirubin:0.125–1.0mg/plate)
all dissolved in DMSO, were used. The concentrations used
were based on the bacterial toxicity, in a preliminary test. In
all subsequentassays, the upperlimit of thedose range tested
was either thehighest non-toxic doseor the lowest toxicdose
determined in this preliminary assay. Toxicity was apparent
either as a reduction in the number of his+ revertants or
as an alteration in the auxotrophic background lawn. The
various concentrations of tested compounds were added to
500μlo fb u ﬀer (pH 7.4) and 100μl of bacterial culture and
then incubated at 37◦C for 20–30 minutes. Next, 2ml of top
agar was added to the mixture and the whole poured on to
a plate containing minimum agar. The plates were incubated
at 37◦C for 48 hours and the his+ revertant colonies were
counted manually. The inﬂuence of metabolic activation was
tested by adding 500μl of S9 mixture (4%) in place of the
buﬀer. All experiments were analyzed in triplicate.
The standard mutagens used as positive controls
in experiments without S9 mix were 4-nitro-o-phenyl-
enediamine (10μg/plate) for TA98 and TA97a, sodium azide
(1.25μg/plate) for TA100 and mitomycin C (0.5μg/plate)
for TA102. 2-anthramine (0.125μg/plate) was used in the
experiments with metabolic activation with all strains.
DMSO served as the negative (solvent) control.
2.6. Statistical Analysis. The statistical analysis was per-
formed with the Salanal computer program, adopting the
Bernstein et al. [19] model. The mutagenic index (MI)
was also calculated for each dose, as the average number
of revertants per plate divided by the average number of
revertants per plate of the negative (solvent) control. A
sample was considered positive when MI ≥2 for at least one
of the tested doses and if the response was dose dependent
[20–22].
3.Results
3.1. Phytochemical Analysis. Portions of the MeOH extracts
from I. truxillensis and I. suﬀruticosa were fractionated by
gel permeation on Sephadex LH-20, leading to the collection
of fractions A–C. Fraction A from both species contained
glycerolipids.
The puriﬁcation of fraction B (ﬂavonoid fraction) from
I. truxillensis yielded the ﬂavonols: kaempferol 3-O-α-l-
rhamnopyranoside (It1, 9mg) and kaempferol 7-O-α-l-
rhamnopyranoside (It2,7mg),kaempferol3-O-α-l-rhamno-
pyranoside-7-O-α-l-rhamnopyranoside (It3,21mg),kaemp-
ferol 3-O-α-l-arabinopyranoside-7-O-α-l-rhamnopyrano-
side (It4, 15mg). The ﬂavonoid fraction from I. suﬀru-
ticosa was also puriﬁed, aﬀording the ﬂavonols quercetin
7-O-β-d-glucopyranoside (Is1, 5mg), quercetin 3-O-[β-
d-xylopyranosyl-(1→2)-β-d-galactopyranoside] (Is2, 10mg),
quercetin 3-O-[α-l-rhamnopyranosyl-(1→ 6)-β-d-glucopy-
ranoside] (Is3, 20mg), quercetin 3-O-[β-d-glucopyranosyl-
(1→2)-β-d-glucopyranoside] (Is4, 8mg). Puriﬁcation of
fraction C (alkaloid fraction) from I. truxillensis and
I. suﬀruticosa g a v et h es a m eb i s - i n d o l ed e r i v a t i v e s :i n d i g o
( I t 5 ,5 m g ;I s 5 ,7 m g )a n di n d i r u b i n( I t 6 ,8 m g ;I s 6 ,5 m g )
(Figure 1).
3.2. Salmonella Mutagenicity Assay. The MeOH extract
as well as the fractions and some isolated compounds
were investigated for their mutagenic activity, using the
Salmonella microsome assay. Table 1 shows the number
of revertants/plate, the SD and the MI values after the
treatments with the extracts and fractions of I. truxillensis,i n
the four diﬀerent strains of S. typhimurium, with or without
metabolic activation. The MeOH extract was mutagenic to
the strain TA98 in absence of metabolic activation (−S9)
and in presence of S9 TA98 did not display mutagenicity.
This strain detects frameshift mutations in the DNA (target
–C–G–C–G–C–G–C–G–). The mutagenic indexes per plate
observed for the strain TA98 were higher than the other
strains used. Fraction A did not display any mutagenicity
and it was not further investigated. Fraction B (ﬂavonoid
fraction) showed signs of mutagenic activity to the strain
TA98 (−S9 and +S9). The values of the MI varied from 1.1
to 1.9, with a signiﬁcant dose-dependent eﬀect (P ≤ .01).
FractionC(alkaloidfraction)alsoshowedsignsofmutagenic
activity, with MI 1.7 and P ≤ .05. These results suggested
that the compounds in the methanol extract that induced
mutagenic activity were present in fractions B and C.
Table 2 shows the results obtained with the MeOH
extract of I. suﬀruticosa and in spite of the negative results
in the mutagenic activity, the MI values are around 2 (TA98-
S9), suggesting the presence of compounds potentially
mutagenic.ForthefractionsA,BandCtheresultsaresimilar
to those obtained for I. truxillensis. The isolated compounds
(from Fraction C) were evaluated and it can be seen in
Table 3 that for indigo and indirubin the mutagenicity was
positive. A signiﬁcant increase in the reversion frequency of
the TA98 strain was observed for indigo with and without
addition of the S9 mixture and for indirubin the mutagenic
eﬀectwasobservedinabsenceofmetabolization.Thehighest
MI value (7.7) was observed for indigo in presence of S9
fraction.
4.Discussionand Conclusions
Plants of the genus Indigofera are known for their eﬃcacy
in popular medicine. Although much work has been done
on the pharmacological properties of extracts from species
belonging to the genus, no data are available in the literature
concerning the genotoxicity of I. truxillensis and I. suﬀru-
ticosa that might guarantee the safe use of these medicinal
plants.
The present study, mutagenic activity assays with
Salmonella demonstrated that the methanol extract of
I. truxillensis induced mutagenic activity in the TA98
strain, ﬂavonoid and alkaloid fractions induced a signiﬁcant
increase in the number of revertants per plate, although MI
was <2. The methanol extract and fractions of I. suﬀruticosa
also induced a signiﬁcant increase in the number of rever-
tants per plate and the MI values are around 2, indicating
signs of mutagenic activity. The phytochemical investigation4 Evidence-Based Complementary and Alternative Medicine
Table 1: Mutagenic activity expressed as the mean and SD of the number of revertants/plate in bacterial strains TA98, TA100, TA97a and
TA102exposedtoMeOHextract andfractionsA,BandCofI.truxillensis atvariousdoses,with(+S9)orwithout(−S9)metabolicactivation.
Treatments mg/plate Revertants/plate in S. typhimurium strains
TA98 TA97a TA100 TA102
−S9(a) +S9(b) −S9(a) +S9(b) −S9(c) +S9(b) −S9(d) +S9(b)
MeOH extract
04 3 ± 2.7 36 ± 2.0 131 ± 1.5 139 ± 2.5 163 ± 4.2 145 ± 9.5 242 ± 9.2 223 ± 11.9
1.25 55 ± 4.6∗
(1.3)
41 ± 2.3
(1.1)
143 ± 5.0
(1.1)
131 ± 2.5
(0.9)
184 ± 8.7
(1.1)
151 ± 14.5
(1.0)
271 ± 4.0
(1.1)
219 ± 7.9
(0.9)
2.50 57 ± 1.5∗∗
(1.3)
38 ± 7.6
(1.1)
143 ± 3.1
(1.1)
129 ± 10.7
(0.9)
186 ± 7.6
(1.1)
145 ± 3.0
(1.0)
254 ± 1.5
(1.0)
223 ± 11.0
(1.0)
3.75 87 ± 2.0∗∗
(2.0)
42 ± 2.0
(1.3)
147 ± 2.1
(1.1)
137 ± 6.8
(0.9)
194 ± 4.0
(1.2)
149 ± 11.9
(1.0)
258 ± 1.0
(1.1)
238 ± 6.7
(1.1)
5.00 77 ± 6.1∗∗
(1.8)
45 ± 4.2
(1.3)
148 ± 5.0
(1.1)
142 ± 16.1
(1.0)
180 ± 6.2
(1.1)
141 ± 7.6
(0.9)
264 ± 4.0
(1.1)
228 ± 5.3
(1.0)
7.50 75 ± 5.0∗∗
(1.7)
51 ±
3.1(1.4)
159 ± 7.8
(1.2)
134 ± 16.0
(0.9)
173 ± 5.0
(1.1)
140 ± 5.5
(0.9)
280 ± 35.6
(1.2)
249 ± 11.0
(1.1)
Fraction A
(glycerolipids)
02 9 ± 2,1 31 ± 2.7 141 ± 8.0 143 ± 4.0 148 ± 2.5 143 ± 5.0 239 ± 16.7 210 ± 11.1
0.12 38 ± 4.6
(1.3)
31 ± 3.6
(1.0)
143 ± 13.5
(1.0)
137 ± 5.3
(0.9)
163 ± 26.1
(1.1)
155 ± 4.2
(1.1)
267 ± 14.1
(1.1)
235 ± 13.1
(1.1)
0.38 32 ± 5.3
(1.1)
30 ± 1.5
(0.9)
138 ± 4.6
(0.9)
143 ± 4.0
(1.0)
151 ± 4.2
(1.0)
149 ± 7.0
(1.0)
247 ± 7.6
(1.0)
236 ± 10.3
(1.1)
0.75 42 ± 13.5
(1.4)
40 ± 4.5
(1.3)
132 ± 7.8
(0.9)
148 ± 3.6
(1.0)
164 ± 13.9
(1.1)
165 ± 13.6
(1.2)
245 ± 5.9
(1.0)
251 ± 5.1
(1.2)
1.50 39 ± 5.6
(1.3)
35 ± 3.6
(1.1)
144 ± 8.4
(1.0)
138 ± 7.6
(0.9)
183 ± 14.1
(1.2)
166 ± 3.1
(1.2)
250 ± 6.1
(1.0)
254 ± 5.6
(1.2)
2.50 40 ± 4.1
(1.4)
39 ± 6.0
(1.3)
138 ± 4.6
(0.9)
143 ± 6.1
(1.0)
173 ± 10.1
(1.2)
175 ± 7.6
(1.2)
251 ± 6.9
(1.0)
255 ± 7.2
(1.2)
Fraction B
(ﬂavonoids)
02 9 ± 2,1 31 ± 2.7 141 ± 8.0 143 ± 4.0 148 ± 2.5 143 ± 5.0 239 ± 16.7 210 ± 11.1
0.12 32 ± 4.0
(1.1)
30 ± 5.9
(0.9)
142 ± 20.0
(1.0)
145 ± 7.9
(1.0)
144 ± 14.2
(0.9)
145 ± 4.2
(1.0)
223 ± 11.0
(0.9)
224 ± 6.0
(1.1)
0.38 40 ± 2.5∗
(1.4)
40 ± 8.7
(1.3)
132 ± 7.0
(0.9)
142 ± 3.1
(0.9)
140 ± 1.5
(0.9)
145 ± 6.5
(1.0)
198 ± 12.5
(0.8)
206 ± 11.4
(0.9)
0.75 42 ± 4.0∗∗
(1.4)
40 ± 7.5
(1.3)
138 ± 3.6
(0.9)
146 ± 5.1
(1.0)
145 ± 13.2
(0.9)
156 ± 12.4
(1.1)
213 ± 23.3
(0.9)
216 ± 17.1
(1.0)
1.50 50 ± 4.9∗∗
(1.7)
49 ± 6.4∗
(1.6)
156 ± 9.3
(1.1)
146 ± 5.9
(1.0)
155 ± 5.0
(1.0)
154 ± 6.5
(1.1)
246 ± 7.4
(1.0)
232 ± 13.6
(1.1)
2.50 57 ±
5.0∗∗(1.9)
49 ± 4.6∗
(1.6)
158 ± 3.2
(1.1)
151 ± 7.8
(1.1)
136 ± 4.6
(0.9)
142 ± 7.9
(0.9)
250 ± 8.5
(1.0)
234 ± 11.0
(1.1)
Fraction C
(alkaloids)
04 3 ± 2.7 36 ± 2.0 131 ± 1.5 139 ± 2.5 163 ± 4.2 145 ± 9.5 242 ± 9.2 223 ± 11.9
0.12 37 ± 4.0
(0.9)
33 ± 5.0
(0.9)
133 ± 4.5
(1.0)
126 ± 6.6
(0.9)
165 ± 3.6
(1.0)
132 ± 3.1
(0.9)
241 ± 7.1
(0.9)
220 ± 4.5
(0.9)
0.38 43 ± 2.5
(1.0)
36 ± 6.0
(1.0)
146 ± 7.0
(1.1)
136 ± 9.1
(0.9)
178 ± 3.1
(1.1)
142 ± 2.0
(0.9)
256 ± 21.6
(1.1)
224 ± 9.9
(1.0)
0.75 44 ± 1.5
(1.0)
34 ± 11.1
(0.9)
136 ± 8.6
(1.0)
133 ± 4.5
(0.9)
183 ± 4.0
(1.1)
144 ± 4.6
(0.9)
294 ± 12.9
(1.2)
223 ± 14.1
(1.0)
1.50 72 ± 9.7∗
(1.7)
45 ± 3.1
(1.3)
152 ± 13.1
(1.2)
146 ± 4.0
(1.1)
189 ± 3.5
(1.1)
141 ± 10.0
(0.9)
310 ± 2.0
(1.3)
224 ± 11.2
(1.0)
Control + 608 ±
71.52 663 ± 35.4 711 ± 12.1 761 ± 28.0 914 ± 17.6 886 ± 49.3 1076 ± 57.1 1082 ± 72.9
MeOH: methanolic extract; 0 = negative control (DMSO—100μl/plate); Control +: Positive control.
(a)4-Nitro-o-phenylenediamine (10.0μg/plate); (b)2-anthramine (1.25μg/plate); (c)Sodium azide (1.25μg/plate); (d)Mitomycin C (0.5μg/plate).
∗P < .05, ∗∗P < .01 (ANOVA). The values in brackets are MI values.Evidence-Based Complementary and Alternative Medicine 5
Table 2: Mutagenic activity expressed as the mean and SD of the number of revertants/plate in bacterial strains TA98, TA100, TA97a and
TA102 exposed to MeOH extract and fractions A, B and C of I. suﬀruticosa, at various doses, with (+S9) or without (−S9) metabolic
activation.
Treatments mg/plate Revertants/plate in S. typhimurium strains
TA98 TA97a TA100 TA102
−S9(a) +S9(b) −S9(a) +S9(b) −S9(c) +S9(b) −S9(d) +S9(b)
MeOH extract
04 3 ± 2.7 36 ± 2.0 131 ± 1.5 139 ± 2.5 163 ± 4.2 145 ± 9.5 242 ± 9.2 223 ± 11.9
1.25 38 ± 4.6
(0.9)
41 ± 1.2
(1.1)
145 ± 3.1
(1.1)
138 ± 2.1
(0.9)
152 ± 4.0
(0.9)
141 ± 2.1
(0.9)
262 ± 2.5
(1.1)
219 ± 4.9
(0.9)
2.50 43 ± 4.5
(1.0)
40 ± 2.7
(1.1)
145 ± 2.1
(1.1)
142 ± 4.2
(1.0)
151 ± 2.1
(0.9)
147 ± 6.7
(1.0)
244 ± 7.6
(1.0)
225 ± 8.5
(1.0)
3.75 62 ± 2.5∗∗
(1.4)
44 ± 3.1
(1.2)
147 ± 4.0
(1.1)
145 ± 2.1
(1.0)
161 ± 2.7
(0.9)
146 ± 7.5
(1.0)
249 ± 6.7
(1.0)
242 ± 5.0
(1.1)
5.00 66 ± 1.5∗∗
(1.5)
44 ± 3.1
(1.2)
153 ± 5.0
(1.2)
142 ± 6.4
(1.0)
165 ± 3.1
(1.0)
152 ± 6.2
(1.0)
250 ± 6.1
(1.0)
234 ± 7.9
(1.0)
7.50 76 ± 5.9∗∗
(1.8)
45 ± 3.5
(1.2)
159 ± 7.8
(1.2)
151 ± 5.1
(1.0)
156 ± 1.5
(0.9)
149 ± 6.0
(1.0)
253 ± 3.5
(1.0)
237 ± 9.6
(1.1)
Fraction A
(glycerolipids)
04 3 ± 2.7 36 ± 2.0 131 ± 1.5 139 ± 2.5 148 ± 2.5 143 ± 5.0 239 ± 16.7 210 ± 11.1
0.12 46 ± 1.7
(1.1)
35 ± 2.0
(0.9)
131 ± 2.1
(1.0)
136 ± 3.5
(0.9)
159 ± 4.2
(1.1)
145 ± 3.0
(1.0)
251 ± 7.0
(1.1)
227 ± 7.6
(1.1)
0.38 47 ± 1.5
(1.1)
38 ± 2.5
(1.1)
134 ± 3.1
(1.0)
135 ± 3.1
(0.9)
160 ± 2.0
(1.1)
147 ± 3.1
(1.0)
260 ± 6.0
(1.1)
235 ± 5.0
(1.1)
0.75 50 ± 1.5
(1.2)
42 ± 1.5
(1.2)
139 ± 5.0
(1.1)
138 ± 1.2
(0.9)
163 ± 3.1
(1.1)
152 ± 2.1
(1.1)
264 ± 8.4
(1.1)
247 ± 5.0
(1.2)
1.50 55 ± 3.6
(1.1)
45 ± 1.6
(1.3)
143 ± 2.5
(1.1)
142 ± 2.1
(1.0)
170 ± 1.5
(1.1)
160 ± 2.0
(1.1)
265 ± 5.0
(1.1)
255 ± 5.0
(1.2)
Fraction B
(ﬂavonoids)
04 3 ± 2.7 36 ± 2.0 131 ± 1.5 139 ± 2.5 148 ± 2.5 143 ± 5.0 239 ± 16.7 210 ± 11.1
0.12 45 ± 1.5
(1.0)
42 ± 2.0
(1.2)
142 ± 1.5
(1.0)
136 ± 2.0
(1.0)
149 ± 4.2
(1.0)
136 ± 3.1
(0.9)
244 ± 3.2
(1.0)
219 ± 8.1
(1.0)
0.38 52 ± 1.5∗
(1.2)
43 ± 4.5
(1.2)
142 ± 1.0
(1.0)
139 ± 1.5
(1.0)
152 ± 3.6
(1.0)
140 ± 2.5
(0.9)
249 ± 2.1
(1.0)
239 ± 6.1
(1.1)
0.75 63 ± 3.1∗∗
(1.5)
48 ± 1.2∗∗
(1.3)
144 ± 3.1
(1.1)
141 ± 2.1
(1.0)
153 ± 5.5
(1.0)
142 ± 2.1
(0.9)
248 ± 26.2
(1.0)
243 ± 5.0
(1.2)
1.50 81 ± 1.5∗∗
(1.9)
54 ±
2.5∗∗(1.5)
149 ± 1.5
(1.1)
144 ± 3.2
(1.0)
158 ± 2.0
(1.1)
143 ± 2.0
(1.0)
272 ± 6.2
(1.1)
264 ± 4.7
(1.3)
Fraction C
(alkaloids)
04 3 ± 2.7 36 ± 2.0 131 ± 1.5 139 ± 2.5 148 ± 2.5 143 ± 5.0 239 ± 16.7 210 ± 11.1
0.12 46 ± 1.5
(1.1)
31 ± 1.7
(0.9)
142 ± 2.0
(1.0)
139 ± 1.2
(1.0)
151 ± 2.3
(1.0)
140 ± 2.7
(0.9)
255 ± 4.2
(1.1)
228 ± 5.7
(1.1)
0.38 50 ± 2.0
(1.2)
38 ± 1.5
(1.1)
146 ± 1.2
(1.1)
139 ± 3.1
(1.0)
153 ± 2.5
(1.0)
145 ± 3.0
(1.0)
269 ± 1.2
(1.1)
239 ± 4.2
(1.1)
0.75 69 ± 1.2∗
(1.6)
40 ± 1.5
(1.1)
152 ± 2.0
(1.0)
143 ± 3.1
(1.0)
165 ± 3.8
(1.1)
149 ± 2.1
(1.0)
278 ± 5.3
(1.2)
243 ± 5.9
(1.2)
1.50 85 ±
1.5∗∗(1.9)
47 ± 1.2
(1.3)
152 ± 4.4
(1.2)
143 ± 1.5
(1.1)
180 ± 2.0
(1.2)
154 ± 2.5
(1.1)
306 ± 7.2
(1.3)
255 ± 4.7
(1.2)
Control + 466 ± 34.1 607 ± 30.3 703 ± 24.7 750 ± 55.7 955 ± 33.0 797 ± 32.1 1158 ± 65.8 1158 ± 49.4
MeOH: methanolic extract; 0 = negative control (DMSO—100μl/plate); Control +: positive control.
(a)4-Nitro-o-phenylenediamine (5.0μg/plate); (b)2-anthramine (1.25μg/plate); (c)Sodium azide (1.25μg/plate); (d)Mitomycin C (0.5μg/plate).
∗P < .05, ∗∗P < .01 (ANOVA). The values in brackets are MI values.6 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Structures of the compounds isolated from the Indigofera species. Fraction B (Flavonoid fraction): I. truxillensis—kaempferol
3-O-α-l-rhamnopyranoside (It1) and kaempferol 7-O-α-l-rhamnopyranoside (It2), kaempferol 3-O-α-l-rhamnopyranoside-7-O-α-l-
rhamnopyranoside (It3) and kaempferol 3-O-α-l-arabinopyranoside-7-O-α-l-rhamnopyranoside (It4); I. suﬀruticosa—quercetin 7-O-β-
d-glucopyranoside (Is1), quercetin 3-O-[β-d-xylopyranosyl-(1→2)-β-d-galactopyranoside] (Is2), quercetin 3-O-[α-l-rhamnopyranosyl-
(1→6)-β-d-glucopyranoside] (Is3) and quercetin 3-O-[β-d-glucopyranosyl-(1→2)-β-d-glucopyranoside] (Is4). Fraction C (Alkaloid
fraction): I. truxillensis and I. suﬀruticosa—indigo (It5, Is5) and indirubin (It6, Is6).
showed that the ﬂavonoids in the methanol extracts are
kaempferol and quercetin glycosides.
In the case of the ﬂavonoids, despite many results indi-
cating their pharmacological activity and potential beneﬁt
to human health [23, 24], several are also described as
mutagens [25, 26]. Among ﬂavonoids, ﬂavonols constitute
a very important subclass as for as genotoxicity studies are
concerned. There are numerous reports on the mutagenicity
ofcompoundsbelongingtothissubclass.Quercetinisknown
to be directly mutagenic to the Salmonella strain TA98
[27–30], whereas ﬂavonoids lacking the adjacent hydroxyl
(catechol groups) are innocuous [31]. Kaempferol has only
one hydroxyl group in the B ring and is a weak mutagen in
both TA98 [27–30]a n dV 7 9[ 32] cells, and this activity is
decreased further when the aglycone is bound to glycosidic
moieties [33].
The indigoidsare natural bis-indolesutilized in dyes[34]
and are being studied for medicinal purposes [35]. They
are founded in plants [36], mushrooms [37]a n dh u m a n
urine [38]. In the human body, indole is a product of the
catabolism of tryptophan by gut bacteria and is signiﬁcantly
absorbed. It is oxidized to indoxyl and excreted in the urine
as indoxyl (3-hydroxyindole) sulfate. Many alkaloids are
known to be genotoxic [39–43]. However, many of these
alkaloids have also demonstrated an outstanding pharma-
cological potential, exhibiting antimicrobial, antiplasmodial
and antitumoral activities [44, 45].
In relation to indigo mutagenicity the data are con-
troversial. Herbert et al. [46] assessed the mutagenicity of
natural indigo by using the standard procedure for the
Salmonella/microsome mutagenicity test, as described by
Ames. The substance exhibited mutagenicity towards strains
TA1538 and TA98 in the presence of S9. On the other
hand, Jongen and Alink [47] investigated the mutagenic
potential of two natural and seven synthetic, commercial
indigo dye products. The natural products showed no
mutagenicity in S. typhimurium strains TA98 and TA100.
The results conﬁrmed the presence of mutagenic activity
and the highest values of MI were obtained when indigo
w a se v a l u a t e d ,s u g g e s t i n gt h a tt h i sa l k a l o i di st h em a i n
compound responsible for the mutagenic eﬀect. Natural
indigo is a dark blue powder obtained from several plant
species, besides the gender Indigofera [48]. It is used in
Chinese traditional medicine [49] for the treatment of virus
infections [50], inﬂammatory breathing diseases [51]a n d
leukemia [52–54]. The bis indole indirubin is an active
ingredient of Danggui Longhui Wan, a traditional Chinese
medicine used in the treatment of chronic diseases such asEvidence-Based Complementary and Alternative Medicine 7
Table 3: Mutagenic activity expressed as the mean and SD of the
number of revertants/plate in bacterial strain TA98 exposed to the
compounds isolated from methanolicextract of I. truxillensis and I.
suﬀruticosaatvariousdoses,with(+S9)orwithout(−S9)metabolic
activation.
Treatment (mg/plate) TA98 (−S9) TA98 (+S9)
Positive control 867 ± 1.4 991 ± 10.1
Negative control 30 ± 1.5 36 ± 4.0
Alkaloids
Indigo
0.125 38 ± 0.6 (1.3) 44 ± 2.7∗ (1.2)
0.25 42 ± 3.2 (1.4) 86 ± 5.3∗∗ (2.4)
0.50 45 ± 1.5 (1.5) 192 ± 2.5∗∗ (5.3)
0.75 50 ± 4.0∗ (1.7) 229 ± 3.6∗∗ (6.7)
1.00 57 ± 4.2∗∗ (1.9) 276 ± 5.3∗∗ (7.7)
Indirubin
0.125 46 ± 2.7 (1.5) 36 ± 2.0 (1.0)
0.25 58 ± 3.8∗∗ (1.9) 36 ± 4.0 (1.0)
0.50 58 ± 3.0∗∗ (1.9) 38 ± 2.5 (1.1)
0.75 63 ± 1.7∗∗ (2.1) 43 ± 4.0 (1.2)
1.00 63 ± 3.6∗∗ (2.1) 46 ± 3.6 (1.3)
Negative control: DMSO (100μl/plate); Positive control: −S9: 4-nitro-o-
phenylenediamine (10.0μg/plate); +S9: 2-anthramine (1.25μg/plate).
∗P < .05, ∗∗P < .01 (ANOVA). The values in brackets are MI values.
leukemia. The antitumoral properties of indirubin appear
to correlate with their antimitotic eﬀect. Indirubins were
recently described as potent inhibitors of cyclin-dependent
kinases [55].
Finally, it may be conclude that mutagenic activity
observed in the methanol extract can probably be attributed
to interaction between several compounds present in these
species and the alkaloid indigo is the main compound
responsible for this eﬀect. The positive results in the Ames
test for the MeOH extract suggest that the indiscriminate use
of homemade preparations of this plant can be dangerous
to health. Like synthetic medicines, natural products also
need to be evaluated with regard to their pharmacological
properties, toxicity,dosage, duration of treatment and safety.
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